


# Optimizing Patient Outcomes for Specialty and Rare Diseases

Specialty and rare diseases are characterized by undefined patient populations that are regularly undiagnosed or misdiagnosed, healthcare providers who are unaware of disease states and their manifestations, as well as treatment journeys that are not well-understood. IPM.ai transforms real world data into real world insights to uncover the ideal patient and their healthcare ecosystem so that life sciences companies can accelerate the commercialization of life-saving therapies for specialty and rare diseases that lead to optimal patient outcomes quicker, with less risk. Examples of the value we provide to clients include:

#### **Patient Finding**



#### **HCP Mapping**



IPM.ai delivered a database covering 94% of patient volume, detailing the magnitude of referring HCPs and diagramming geographic network visualization.



IPM.ai affiliated 84% of referring physicians to institutions for a client preparing a study of a neurodegenerative disease with complex symptomatology.



IPM.ai delivered a database with 13,000 top-decided HCPs accounting for 60% of total patient volume to a client with a first-in-market treatment.

## ໍ **11,000**

IPM.ai uncovered 11,000 high-value treaters for a specialty neuromuscular treatment, including 47% more high-value neurologists.





IPM.ai found ~7,000 HCPs treating hidden patients for a disease with less than 2,000 patients, raising the positive-patient ID rate to more than 10%.

IPM.ai developed a database prioritizing HCPs seeing the 4,000 most likely patients for a client's early-stage program for a rare genetic condition.

### About IPM.ai

IPM.ai (www.ipm.ai), part of Real Chemistry, is an Insights as a Service (IaaS) provider that empowers the world's leading life sciences companies to better understand and improve the lives of patients through the commercialization of precision medicine for specialty and rare diseases. IPM.ai's system of insight optimizes drug development, clinical study, product launch and commercial operations by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real world data universe of over 300 million de-identified patient journeys and 65 billion anonymized social determinants of health signals.